Emergent and Proposed Acquisition Partner Regen Biowellness to Re-Launch FDA Registered Patented Immune Booster ImmunaZin(TM) To Significantly Increase Revenues

Author's Avatar
Jul 12, 2022

HAUPPAUGE, NY / ACCESSWIRE / July 12, 2022 / Emergent Health Corp. ("Emergent") (OTC PINK:EMGE) announces that upon its anticipated acquisition of Regen Biowellness ("Regen") this month, it intends to re-launch Regens FDA Registered Immune Booster supplement ImmunaZin™ to significantly increase Revenues.